Welcome to the Starpharma investor centre.

Starpharma Holdings Limited is an Australian stock exchange listed biotechnology company with products based on its dendrimer technology platform.

asx.jpg

View All
ASX Announcements

 

Need to update your
shareholder details

 

Download 
Annual Report

View the 
Analyst coverage

 

Have an
Investor query?

 

Register here
for email updates

Latest News & Announcements

Click here for news archive

Quarterly Cashflow and Activities Report (ASX Announcement)

Apr 29th, 2022

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2022.

Read More

Starpharma to present DEP® at Boston ADC summit (ASX Announcement)

Apr 27th, 2022

Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it will today present as an invited speaker at the Novel Format Conjugates Summit, an industry conference focusing on next generation Non-Traditional Antibody Drug Conjugates (ADCs) for oncology and beyond.

Read More

VIRALEZE™ to relaunch in the UK (ASX Announcement)

Apr 1st, 2022

Starpharma today announced that it has successfully resolved the queries raised last year by the UK Medicines and Healthcare products Regulatory Agency (MHRA), clearing the way for the relaunch of VIRALEZE™ in the UK as soon as possible.

Read More

SPL7013 in VIRALEZE™ virucidal against Omicron (ASX Announcement)

Mar 1st, 2022

Starpharma today announced that SPL7013, the antiviral agent in VIRALEZE™ antiviral nasal spray, achieved the maximal possible reduction of virus infectivity (>95% within 1 minute of exposure and >99% within 5 minutes, achieving a maximal reduction of >99.5%) against the Omicron variant of SARS-CoV-2, in laboratory-based antiviral and virucidal assays. Testing of SPL7013 against Omicron was conducted in the laboratory of internationally recognised virologist, Professor Philippe Gallay, at The Scripps Research Institute in the US.

Read More

Reports & Presentations

Click here for financial reports archive

Quarterly Cashflow and Activities Report (ASX Announcement)

Apr 29th, 2022

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2022.

Read More

Quarterly Cashflow and Activities Report (ASX Announcement)

Jan 28th, 2022

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 December 2021.

Read More

AGM Chairman’s address and CEO’s presentation (ASX Announcement)

Nov 30th, 2021

Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting (AGM) of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 11am (Melbourne time) today.

Read More

Starpharma to present at Bell Potter Healthcare Conference (ASX Announcement)

Nov 9th, 2021

Starpharma has been invited to present today at the exclusive virtual 2021 Bell Potter Healthcare Conference. The Bell Potter Healthcare Conference showcases leading companies within the Australian healthcare sector and brings together industry leaders with Bell Potter’s network of international and domestic investors, analysts and advisers. The event is available to live-stream via Bell Potter Client Access on 9 – 11 November.

Read More

Quarterly Cashflow and Activities Report (ASX Announcement)

Oct 29th, 2021

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 September 2021.

Read More

Starpharma annual report and full year financial results (ASX Announcement)

Aug 26th, 2021

Starpharma today released its annual report and financial results for the year ended 30 June 2021.

 

Read More

Starpharma to present at Virtual Life Sciences Investor Forum (ASX Announcement)

Jun 24th, 2021

Starpharma today announced that a presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 24 June 2021 (US ET) as part of OTCQX’s Virtual Life Sciences Investor Forum. The Life Sciences Investor Forum is a leading investor conference that is attended by tens of thousands of investors, primarily US-based retail investors, as well as advisors.

Read More